UBS lowered the firm’s price target on Bio-Rad (BIO) to $310 from $355 and keeps a Buy rating on the shares. Bio-Rad reported a quarterly but, but guidance was lower on the macro environment, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: